ArticleVaccine2017
Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04059510 (opTImisation of Methods for a Human INfection Model for Group B Streptococcus), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
opTImisation of Methods for a Human INfection Model for Group B Streptococcus
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.Nature communications · 2026Article
- Maternal cytokine profile and anti-bacterial specific antibody response associated with neonatal infection by E. coli and K. pneumoniae.BMC infectious diseases · 2026Article
- Diversity in Naturally Acquired Immunity to Group B Streptococcus: A Comparative Study of Women From Bangladesh, Malawi, and the United Kingdom.The Journal of infectious diseases · 2025Article
- Article
- Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma.Methods in molecular biology (Clifton, N.J.) · 2022Article
- The Impact of Circulating Antibody on Group BInfection and immunity · 2020Article
- Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus.Human vaccines & immunotherapeutics · 2020Article
- A Vaccine Against Group BInfection and drug resistance · 2020Review
- Streptococcus agalactiae in pregnant women in Brazil: prevalence, serotypes, and antibiotic resistance.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2019Review
- Group B Streptococcus Biofilm Regulatory Protein A Contributes to Bacterial Physiology and Innate Immune Resistance.The Journal of infectious diseases · 2018Article
- Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges.Frontiers in immunology · 2018Review
- Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches.Frontiers in pediatrics · 2018Review
- Codevelopment of Microbiota and Innate Immunity and the Risk for Group B Streptococcal Disease.Frontiers in immunology · 2017Review
- SIgA, TGF-β1, IL-10, and TNFα in Colostrum Are Associated with Infant Group BFrontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundVertical transmission of Group B Streptococcus (GBS) is a prerequisite for early-onset disease and a consequence of maternal GBS colonization. Disease protection is associated with maternally-derived anti-GBS antibody. Using a novel antibody-mediated C3b/iC3b deposition flow cytometry assay which correlates with opsonic killing we developed a model to assess the impact of maternally-derived functional anti-GBS antibody on infant GBS colonization from birth to day 60-89 of life.
methodsRectovaginal swabs and cord blood (birth) and infant nasopharyngeal/rectal swabs (birth, day 6 and day 60-89) were obtained from 750 mother/infant pairs. Antibody-mediated C3b/iC3b deposition with cord and infant sera was measured by flow cytometry.
resultsWe established that as maternally-derived anti-GBS functional antibody increases, infant colonization decreases at birth and up to three months of life, the critical time window for the development of GBS disease. Further, we observed a serotype (ST)-dependent threshold above which no infant was colonized at birth. Functional antibody above the upper 95th confidence interval for the geometric mean concentration was associated with absence of infant GBS colonization at birth for STII (p<0.001), STIII (p=0.01) and STV (p<0.001). Increased functional antibody was also associated with clearance of GBS between birth and day 60-89.
conclusionsHigher concentrations of maternally-derived antibody-mediated complement deposition are associated with a decreased risk of GBS colonization in infants up to day 60-89 of life. Our findings are of relevance to establish thresholds for protection following vaccination of pregnant women with future GBS vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.